Abstract
Ischemic stroke is a common neurological disorder lacking a cure. Recent studies show that therapeutic hypothermia is a promising neuroprotective strategy against ischemic brain injury. Several methods to induce therapeutic hypothermia have been established; however, most of them are not clinically feasible for stroke patients. Therefore, pharmacological cooling is drawing increasing attention as a neuroprotective alternative worthy of further clinical development. We begin this review with a brief introduction to the commonly used methods for inducing hypothermia; we then focus on the hypothermic effects of eight classes of hypothermia-inducing drugs: the cannabinoids, opioid receptor activators, transient receptor potential vanilloid, neurotensins, thyroxine derivatives, dopamine receptor activators, hypothermia-inducing gases, adenosine, and adenine nucleotides. Their neuroprotective effects as well as the complications associated with their use are both considered. This article provides guidance for future clinical trials and animal studies on pharmacological cooling in the setting of acute stroke.
Keywords: Brain ischemia, hypothermic, neuroprotection, pharmacological cooling.
CNS & Neurological Disorders - Drug Targets
Title:Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
Volume: 12 Issue: 3
Author(s): Meijuan Zhang, Haiying Wang, Jinbing Zhao, Cong Chen, Rehana K. Leak, Yun Xu, Peter Vosler, Jun Chen, Yanqin Gao and Feng Zhang
Affiliation:
Keywords: Brain ischemia, hypothermic, neuroprotection, pharmacological cooling.
Abstract: Ischemic stroke is a common neurological disorder lacking a cure. Recent studies show that therapeutic hypothermia is a promising neuroprotective strategy against ischemic brain injury. Several methods to induce therapeutic hypothermia have been established; however, most of them are not clinically feasible for stroke patients. Therefore, pharmacological cooling is drawing increasing attention as a neuroprotective alternative worthy of further clinical development. We begin this review with a brief introduction to the commonly used methods for inducing hypothermia; we then focus on the hypothermic effects of eight classes of hypothermia-inducing drugs: the cannabinoids, opioid receptor activators, transient receptor potential vanilloid, neurotensins, thyroxine derivatives, dopamine receptor activators, hypothermia-inducing gases, adenosine, and adenine nucleotides. Their neuroprotective effects as well as the complications associated with their use are both considered. This article provides guidance for future clinical trials and animal studies on pharmacological cooling in the setting of acute stroke.
Export Options
About this article
Cite this article as:
Zhang Meijuan, Wang Haiying, Zhao Jinbing, Chen Cong, Leak Rehana K., Xu Yun, Vosler Peter, Chen Jun, Gao Yanqin and Zhang Feng, Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?, CNS & Neurological Disorders - Drug Targets 2013; 12 (3) . https://dx.doi.org/10.2174/1871527311312030010
DOI https://dx.doi.org/10.2174/1871527311312030010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting TRPs in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Age-Dependent Microglial Activation in Immature Brains After Hypoxia- Ischemia
CNS & Neurological Disorders - Drug Targets Twin-to-Twin Transfusion Syndrome: From Placental Anastomoses to Long-Term Neurodevelopmental Outcome
Current Pediatric Reviews Quantitative Ultrasound in Diagnosis of Metabolic Bone Diseases
Current Medical Imaging BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Gene Therapy Approaches for Neuroprotection and Axonal Regeneration after Spinal Cord and Spinal Root Injury
Current Gene Therapy Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Viewpoints on Medical Image Processing: From Science to Application
Current Medical Imaging CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Increasing Neurogenesis with Fluoxetine, Simvastatin and Ascorbic Acid Leads to Functional Recovery in Ischemic Stroke
Recent Patents on Drug Delivery & Formulation A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery Through the Blood-brain Barrier to the Central Nervous System
CNS & Neurological Disorders - Drug Targets Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design <i>Lantana undulata</i> Schrank – A New Source of Biological Potential in the Verbenaceae Family
The Natural Products Journal An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease
Current Alzheimer Research Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine